Related: Listen: Episode 7: How much are we willing to pay for cures? Listen: Episode 16: To make big profits, drug companies turn to monopoly shenanigans Subscribe to Signal on iTunes or Stitcher or Google Play. Catch our previous episodes here, or sign up below for alerts.The podcast is produced by Jocelyn Gonzales. Co-host “The Readout LOUD,” CNBC senior health and science reporter Episode 6: Choosing scientific sides in the fight against Alzheimer’s Related: Related: Listen: Episode 18: How our next president could affect drug prices Episode 1: We are a constellation of our microbiome and ourselves Related: Related: Episode 2: For boys with Duchenne, and two drug companies, a moment of shared hope Related: Related: Listen: Episode 14: The Chinese hamsters that helped birth biotech Listen: Episode 10: Cancer is a low-down, dirty gangster ninja Related: Listen: Episode 9: How our perceptions of risk — and killer snails! — affect our health Episode 4: A shoppers guide to the genome sequencing market Signal PodcastListen: Episode 19: From poop transplants to pill politics, here’s the year in ‘Signal’ Related: @megtirrell Related: Listen: Episode 13: The superbugs are winning the battle against us Related: WE MADE IT.The “Signal” podcast is now a year old. And in this first year, we’ve been able to cover so much truly fascinating science.Looking back at some of the subjects of podcasts past, it’s clear to us how much things have changed — and how much the understanding of science and medicine can evolve in single year.advertisement Listen: Episode 8: How Wall Street reacts when a patient dies in a clinical trial Listen: Episode 15: Can scientists keep pace with Zika to develop a vaccine? Episode 3: Should we believe published scientific research? Related: Tags Alzheimer’smicrobiomepolitics About the Authors Reprints Listen: Episode 12: Before you pop that Tylenol, tune into this podcast Related: Listen: Episode 11: Sexism in biotech, from scantily clad models to how gender affects this podcast Related: By Luke Timmerman and Meg Tirrell Dec. 9, 2016 Reprints Related: Related: Meg Tirrell Listen: Episode 17: Gene-editing might eradicate disease — or be Pandora’s box in a bottle Molly Ferguson for STAT Episode 5: How biotech went from a risky investment to a booming business In this episode, we jump into our time machine to look back at human fecal matter transplants; drugs aimed at Duchenne muscular dystrophy and Alzheimer’s; deaths in clinical trials; the cost of cures vs. drug prices; and the politics of medicine.Thanks for making our first year such a roaring success, dear listeners (200,000 of you out there decided to download or play “Signal” since our launch). Much more to come — even before this year is over.advertisement Related: Related:
About the Author Reprints Rates of flu are skyrocketing in the U.S., with the Centers for Disease Control and Prevention tracking high rates especially in the South, Midwest, Southwest, and West.Lost in the flurry of news stories is the startling and alarming report from the CDC in December that only about one-third of pregnant women are getting flu shots. A startling 64 percent of pregnant women had not been vaccinated against the flu, despite recommendations from the CDC, the American Academy of Pediatrics, and the American College of Obstetricians and Gynecologists.While 98 percent of pregnant women reported visiting a doctor or other medical professional at least once before or during pregnancy, the CDC found that only about 59 percent reported receiving a recommendation for and offer of flu vaccination from a doctor or other medical professional, while 16 percent received only a recommendation for — but no offer of — the vaccine. A whopping 26 percent received neither a recommendation for nor an offer of flu vaccination.advertisement First OpinionTwo-thirds of pregnant women aren’t getting the flu vaccine. That needs to change Tags infectious diseaseinfluenzapediatricswomen’s health A pregnant woman gets vaccinated against the flu at a Boston hospital. Lisa Poole/AP By Mark N. Simon Jan. 18, 2018 Reprints I work for a company that develops and manages obstetric and gynecology hospitalist programs at more than 100 hospitals across the country. Our doctors have been seeing an increase in pregnant women in the emergency department. At least one flu-related death of a pregnant woman, in Tennessee, has been reported.Pregnant women and their unborn babies are especially vulnerable to influenza and are more likely to develop serious complications from it. About one-third of cases of pneumonia are caused by respiratory viruses, the most common of which is influenza. Pneumonia and other complications increase the risk of preterm labor. Babies in utero are also at risk of complications: Pregnant women who develop the flu are more likely to give birth to children with birth defects of the brain and spine.advertisement Related: Related: If a pregnant woman begins to experience symptoms of the flu, such as cough, fever, sore throat, muscle or body aches, fatigue, or headaches, which can be subtle at first, she should be seen immediately by a physician or midwife to diagnose the flu, or rule it out, as early as possible. Pregnant women with the flu will see the best resolution of their symptoms when they are able to start on antiviral medication within 48 hours of symptom onset.Keeping pregnant women out of the main emergency department to keep them from mingling with potentially infectious patients with flu-like symptoms is also important. When a pregnant woman is sick enough to necessitate a trip to the emergency department, having a dedicated obstetric emergency department can ensure that pregnant women are seen and triaged in the best location for them and can speed the diagnosis and treatment of the flu.These are important takeaways as we reach the peak of the flu season. In the long run, though, we must channel our concerns about the low rate of pregnant women who get vaccinated against the flu into a broader dialogue on strategies for improvement. With intent and purpose, we can increase the vaccination rate and improve care and outcomes for pregnant women and their babies, even in the height of flu season.Mark N. Simon, M.D., is chief medical officer of Ob Hospitalist Group, the nation’s largest provider of obstetric hospitalist programs. Mark N. Simon Pregnant women who need medications face a risky guessing game. A federal task force is now trying to help [email protected] ‘The problem child of seasonal flu’: Beware this winter’s virus @obhgcares Flu shots not only protect mothers, but also confer passive immunity on unborn babies, providing them with antibodies against the virus in the first six months after birth.So why aren’t more pregnant women vaccinated against the flu?Despite efforts by the medical community to quell public health myths, there is confusion about whether these vaccines are safe for pregnant women and their babies. Despite a wide body of evidence about the safety of flu vaccines for women and their babies, misinformation about thimerosal, an ethyl-mercury-based preservative used in multidose vials to safeguard against contamination of the vial, still circulates on the internet, despite multiple studies that demonstrate no evidence of harm. In addition, thimerosol-free versions of the vaccine are readily available.A few simple steps can help keep pregnant women safer and healthier. First, having policies in place to let patients get the flu vaccine without a new order from a physician or midwife would serve as a stopgap for missed opportunities to vaccinate, particularly for the one-quarter of pregnant women who are not informed about the flu vaccine or offered it. Quality metrics for care organizations should also consider whether obstetricians are offering and providing medically recommended vaccinations as part of their quality review for patient safety.
GET STARTED By Ed Silverman June 4, 2018 Reprints What’s included? Pharmalot About the Author Reprints Tags drug pricingpharmaceuticalsSTAT+ Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. @Pharmalot STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Jacques Brinon/AP Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Sanofi is the latest drug maker to say average net prices fell last year What is it? Log In | Learn More Ed Silverman [email protected] Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED Amid heated controversy over drug prices, Sanofi (SNY) is the latest large pharmaceutical company to release top-line numbers indicating average prices for its medicines fell last year, after accounting for rebates and discounts.Specifically, the company posted a brief summary stating the average wholesale — or list— price for its drugs increased 1.6 percent in 2017, but pricing actually declined by 8.5 percent when subtracting rebates and discounts paid to pharmacy benefit managers, or PBMs, and health plans. In 2016, the average price hike was 4 percent, but the net price fell 2.1 percent.
Biotech By Matthew Herper Sept. 12, 2019 Reprints STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. First 30 days free. GET STARTED Matthew Herper [email protected] Log In | Learn More Dr. David Fajgenbaum has nearly died not once, but five times. The cause each time was a rare disorder called Castleman disease, an affliction on the boundary between cancer and an autoimmune disorder. It caused his entire body to swell up. Previously a muscled college football player, he first became bloated, then very thin.Fajgenbaum, who was in medical school when he got sick, did something extraordinary. He founded a patient advocacy group, the Castleman Disease Collaborative Network. But more than that, he delved into the science of his disease, and proposed the treatment that, after five relapses, has kept him healthy since. It was an existing drug, sirolimus, that no one had thought to use for Castleman disease. Football, he said, helped him deal with the failure inherent in medical research.Now 34, Fajgenbaum details his experience in a new book, “Chasing My Cure,” in which he also writes about his mother’s death from brain cancer and the way the disease affected every aspect of his life, including his relationship with his wife. He’s an assistant professor of medicine in the Division of Translational Medicine and Human Genetics at the University of Pennsylvania in Philadelphia. @matthewherper Senior Writer, Medicine, Editorial Director of Events Matthew covers medical innovation — both its promise and its perils. What’s included? GET STARTED Dr. David Fajgenbaum answers questions from a young woman who has been diagnosed with Castleman disease and her mother in his office at the University of Pennsylvania. Jessica Kourkounis About the Author Reprints Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. What is it? After nearly dying five times, a young doctor learned to treat himself. Now he wants to help others with rare disease Tags biotechnologycancerdrug developmentpatient advocacy
Alex Hogan/STAT Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Ed Silverman Log In | Learn More @Pharmalot Hello, everyone, and how are you today? We are doing just fine, thank you, courtesy of clear and sunny skies hovering over the Pharmalot campus, which has settled down now that the short person has left for the local schoolhouse. This leaves us to engage in our usual rituals. You know the drill — we are firing up the coffee kettle for a cup of stimulation and getting our to-do list in order. Never a day goes by without a to-do list, yes? So time to get cracking. Here are some tidbits to help you on your own journey. Hope today is successful and do keep in touch…Researchers have started to recruit healthy Seattle-area volunteers to participate in the first clinical trial of an experimental coronavirus vaccine, a faster-than-expected start for the first vaccine readied for testing, The Wall Street Journal notes. Kaiser Permanente Washington Health Research Institute in Seattle said Wednesday it aims to enroll 45 adults from the region in the trial. The study will test the safety of various doses of the vaccine developed by Moderna (MRNA) and whether the shots produce an immune response. What is it? [email protected] Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED What’s included? STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Pharmalittle: Coronavirus vaccine testing starts in Seattle area; New Mexico law caps monthly insulin co-pay at $25 About the Author Reprints Pharmalot Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. By Ed Silverman March 5, 2020 Reprints GET STARTED Tags pharmalittleSTAT+
With Everest Medicines’ $451 million listing now in the rear-view mirror, health care-focused CBC Group is paving the way for another portfolio company to IPO. But, first, a merger.AffaMed Therapeutics announced last week that it is merging with EverInsight Therapeutics, another biopharmaceutical company. Both firms were founded by CBC, formerly known as C-Bridge Capital. CBC Group sets up AffaMed, EverInsight merger, eyes IPO Biotech About the Author Reprints GET STARTED Log In | Learn More By Jonathan Chan Oct. 20, 2020 Reprints What is it? @JChanPharma Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Jonathan Chan STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. What’s included? [email protected] Tags biotechnologyChinaSTAT+ Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED